Biogen (BIIB) PT Raised to $408 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $254.46 +2.22%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.
Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Flutter Entertainment (FLUT) PT Lowered to $124 at Stifel
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
